Retronectin-induced T cell therapy - Takara Bio

Drug Profile

Retronectin-induced T cell therapy - Takara Bio

Alternative Names: Cancer immunity reconstruction therapy; Cell-based cancer immunotherapy

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takara Bio
  • Developer Kyoto Prefectural University of Medicine; Takara Bio; Tianjin Medical University Cancer Institute and Hospital
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top